Published 1 year ago

Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients

Summary by Ground News

Bempedoic acid (Nexletol,Esperion) lowered LDL cholesterol by 21% in the study. The drug was also well-tolerated in the mixed population of primary and secondary prevention patients unable or unwilling to take statins. "These findings establish bempedoic acid as an effective approach to reduce major cardiovascular events in statin-intolerant patients," the study chair concluded.

0 Articles

All

Left

Center

Right

Medscape

Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients

The CLEAR Outcomes trial establishes this new drug as an important addition to available nonstatin LDL-lowering therapies, experts say.

1 year ago·United States

Read Full Article

Healio

Bempedoic acid an ‘effective alternative’ for statin-intolerant patients: CLEAR Outcomes

NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.